Stock 1093 CSPC PHARMACEUTICAL GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Delayed Hong Kong S.E.
Other stock markets
 11:59:59 2024-05-23 pm EDT 		5-day change 1st Jan Change
6.4 HKD -0.62% Intraday chart for CSPC Pharmaceutical Group Ltd. -3.32% -11.85%
May. 17 CSPC Pharma Gets Clearance for China Clinical Trial of Drug for Metabolism-Related Diseases MT
May. 17 CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug Obtains Approval from National Medical Products Administration of the People's Republic of China CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business Achievements
AQ
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
AQ
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "OSELTAMIVIR PHOSPHATE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "ALOGLIPTIN BENZOATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "SORAFENIB TOSYLATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - PASSING OF CONSISTENCY EVALUATION FOR "DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION"
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "SITAGLIPTIN PHOSPHATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL FIRST-IN-CLASS PRODUCT SYSA1801 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
PU
CSPC Pharmaceutical : CONNECTED TRANSACTION - DISPOSAL OF 49.5% EQUITY INTEREST IN JOINT VENTURE COMPANY /CONTINUING CONNECTED TRANSACTIONS - MASTER PURCHASE AGREEMENT
PU
CSPC Pharmaceutical : INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2021
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NBL-012 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKETING APPROVAL OF "DUVELISIB CAPSULES" ACCEPTED BY NMPA
PU
PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 18 MAY 2021 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)
PU
CSPC Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO BUY-BACK SHARES AND TO ISSUE SHARES AND MANDATE TO GRANT OPTIONS, RE-ELECTION OF THE RETIRING DIRECTORS, AND NOTICE OF ANNUAL GENERAL MEETING
PU
CSPC Pharmaceutical : INVESTIGATIONAL NEW DRUG NBL-015 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - "AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)"
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
PU
CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
PU
CSPC Pharmaceutical : ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1093 Stock
  4. News CSPC Pharmaceutical Group Ltd.
  5. Press Releases